Despite notable improvements in colorectal cancer treatment, the prognosis of patients with metastatic colorectal cancer remains poor, with a median overall survival of approximately 30 months. Immunotherapy represents a novel therapeutic approach for a variety of cancers. However, immunotherapy shows little or no clinical activity in the majority of colorectal cancer patients. A better understanding of the molecular mechanisms that define the immune competence of mCRC is needed to develop predictive biomarkers and effective therapeutic combination strategies. We have found that increase in ketogenesis decreases transcriptional factor KLF5 expression and enhances the efficacy of immunotherapy for colorectal cancers.
This postdoc candidate will learn how to perform the in vitro experiments using cancer cell lines and in vivo mouse experiments. He will perform experiments to determine whether targeting KLF5 can enhance the efficacy of anti-tumor immunotherapy for colorectal cancers.
To be considered for this position you will need to fully complete the application and upload the following documents: CV, Cover Letter, PhD transcript.